Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future

Translational Neurodegeneration

Volumn 4, Issue 1, 2015, Pages

  Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; ETIRACETAM; FIPAMEZOLE; ISTRADEFYLLINE; LEVODOPA; MAVOGLURANT; NORTRIPTYLINE; OPICAPONE; OXYBUTYNIN; PAROXETINE; PERAMPANEL; PRAMIPEXOLE; PROSAVIN; RASAGILINE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SELEGILINE; TALAMPANEL; TOLCAPONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZONISAMIDE;

ANXIETY DISORDER; BLADDER DYSFUNCTION; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; GENE THERAPY; HUMAN; INCIDENCE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; WEARING OFF;

EID: 84929300127     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-4-3     Document Type: Review

References (99)

1. Aquino CC, Fox SH: Clinical spectrum of levodopa-induced complications. Mov Disord 2015, 30:80-89. 10.1002/mds.26125.
2. Connolly BS, Lang AE: Pharmacological treatment of Parkinson disease: a review. JAMA 2014, 311:1670-83. 10.1001/jama.2014.3654.
3. Sharma JC, Ross IN, Rascol O, Brooks D: Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008, 15:493-6. 10.1111/j.1468-1331.2008.02106.x.
4. Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al.: Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013, 28:1064-71. 10.1002/mds.25364.
5. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, Group NV: The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011, 26:399-406. 10.1002/mds.23462.
6. Halliday G, Lees A, Stern M: Milestones in Parkinson's disease-clinical and pathologic features. Mov Disord 2011, 26:1015-21. 10.1002/mds.23669.
7. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K: Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006, 21:2042-51. 10.1002/mds.21065.
8. AlDakheel A, Kalia LV, Lang AE: Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 2014, 11:6-23. 10.1007/s13311-013-0218-1.
9. Fox SH: Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs 2013, 73:1405-15. 10.1007/s40265-013-0105-4.
10. Fox SH, Brotchie JM, Lang AE: Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008, 7:927-38. 10.1016/S1474-4422(08)70214-X.
11. Obeso JA, Rodriguez-Oroz MC, Stamelou M, Bhatia KP, Burn DJ: The expanding universe of disorders of the basal ganglia. Lancet 2014, 384:523-31. 10.1016/S0140-6736(13)62418-6.
12. Schrag A, Quinn N: Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000,123(Pt 11):2297-305.
13. Jenner P: The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 2003, 61:S4-11. 10.1212/WNL.61.6_suppl_3.S4.
14. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al.: Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007, 22:2409-17. 10.1002/mds.21743.
15. Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al.: The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 2014, 137:2731-42. 10.1093/brain/awu195.
16. Fox SH, Lang AE: 'Don't delay, start today': delaying levodopa does not delay motor complications. Brain 2014, 137:2628-30. 10.1093/brain/awu212.
17. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, et al.: Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008, 71:474-80. 10.1212/01.wnl.0000310812.43352.66.
18. Group PDMC, Gray R, Ives N, Rick C, Patel S, Gray A, et al.: Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014, 384:1196-205. 10.1016/S0140-6736(14)60683-8.
19. Jenner P: Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008, 9:665-77. 10.1038/nrn2471.
20. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, et al.: Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005, 57:17-26. 10.1002/ana.20296.
21. Blanchet P, Bedard PJ, Britton DR, Kebabian JW: Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. J Pharmacol Exp Ther 1993, 267:275-9.
22. Cenci MA: Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol 2014, 5:242.
23. Brotchie J, Jenner P: New approaches to therapy. Int Rev Neurobiol 2011, 98:123-50.
24. Fahn S: How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both? Ann Neurol 2008,64(Suppl 2):S56-64.
25. Jankovic J, Stacy M: Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007, 21:677-92. 10.2165/00023210-200721080-00005.
26. Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, et al.: Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014, 82:300-7. 10.1212/WNL.0000000000000050.
27. Aoki FY, Sitar DS: Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988, 14:35-51. 10.2165/00003088-198814010-00003.
28. Morin N, Di Paolo T: Pharmacological treatments inhibiting levodopa-induced dyskinesias in MPTP-lesioned monkeys: brain glutamate biochemical correlates. Front Neurol 2014, 5:144.
29. Loschmann PA, De Groote C, Smith L, Wullner U, Fischer G, Kemp JA, et al.: Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 2004, 187:86-93. 10.1016/j.expneurol.2004.01.018.
30. Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD: NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 2004, 47:184-94. 10.1016/j.neuropharm.2004.03.011.
31. Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, et al.: Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord 2012, 27:284-8. 10.1002/mds.23983.
32. Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, et al.: Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 2012, 35:15-20. 10.1097/WNF.0b013e318241520b.
33. Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, et al.: Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord 2010, 25:896-905. 10.1002/mds.22974.
34. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, et al.: AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011, 26:1243-50. 10.1002/mds.23616.
35. Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, et al.: AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013, 28:1838-46. 10.1002/mds.25561.
36. Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B: Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 2014, 20:947-56. 10.1016/j.parkreldis.2014.05.003.
37. Zaccara G, Giovannelli F, Cincotta M, Verrotti A, Grillo E: The adverse event profile of perampanel: meta-analysis of randomized controlled trials. Eur J Neurol 2013, 20:1204-11. 10.1111/ene.12170.
38. Johnston TH, Brotchie JM: Drugs in development for Parkinson's disease: an update. Curr Opin Investig Drugs 2006, 7:25-32.
39. Kalia LV, Brotchie JM, Fox SH: Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Mov Disord 2013, 28:131-44. 10.1002/mds.25273.
40. Munoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, et al.: Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-94. 10.1093/brain/awn235.
41. Carta M, Carlsson T, Kirik D, Bjorklund A: Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-33. 10.1093/brain/awm082.
42. Verhagen ML: Recognition and treatment of response fluctuations in Parkinson's disease: review article. Amino Acids 2002, 23:141-5. 10.1007/s00726-001-0119-1.
43. Stocchi F, Antonini A, Barone P, Tinazzi M, Zappia M, Onofrj M, et al.: Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 2014, 20:204-11. 10.1016/j.parkreldis.2013.10.027.
44. Stocchi F, Jenner P, Obeso JA: When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol 2010, 63:257-66. 10.1159/000300647.
45. Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, et al.: Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989, 39:11-9.
46. Papa SM, Engber TM, Kask AM, Chase TN: Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994, 662:69-74. 10.1016/0006-8993(94)90796-X.
47. Thomas A, Bonanni L, Di Iorio A, Varanese S, Anzellotti F, D'Andreagiovanni A, et al.: End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. J Neurol 2006, 253:1633-9. 10.1007/s00415-006-0320-z.
48. Ramirez-Zamora A, Molho E: Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions. Expert Rev Neurother 2014, 14:93-103. 10.1586/14737175.2014.868306.
49. Poewe W, Antonini A: Novel formulations and modes of delivery of levodopa. Mov Disord 2015, 30:114-120. 10.1002/mds.26078.
50. Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al.: Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord 2014, 20:142-8. 10.1016/j.parkreldis.2013.08.017.
51. Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, et al.: Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord 2014, 20:1335-40. 10.1016/j.parkreldis.2014.08.004.
52. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, et al.: Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014, 383:1138-46. 10.1016/S0140-6736(13)61939-X.
53. Hauser RA, Schapira AH, Barone P, Mizuno Y, Rascol O, Busse M, et al.: Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. Eur J Neurol 2014, 21:736-43. 10.1111/ene.12375.
54. Nomoto M, Mizuno Y, Kondo T, Hasegawa K, Murata M, Takeuchi M, et al.: Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neurol 2014, 261:1887-93. 10.1007/s00415-014-7427-3.
55. Hattori N, Nomoto M, Study G: Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2014, 20:819-23. 10.1016/j.parkreldis.2014.04.008.
56. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S: Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1998, 50:S54-9. 10.1212/WNL.50.5_Suppl_5.S54.
57. Olanow CW: Tolcapone and hepatotoxic effects. Tasmar advisory panel. Arch Neurol 2000, 57:263-7. 10.1001/archneur.57.2.263.
58. Tolosa E, Hernandez B, Linazasoro G, Lopez-Lozano JJ, Mir P, Marey J, et al.: Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial. J Neural Transm 2014, 121:357-66. 10.1007/s00702-013-1114-x.
59. Bonifacio MJ, Torrao L, Loureiro AI, Palma PN, Wright LC, Soares Da Silva P: Pharmacological profile of opicapone, a third generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Brit J Pharmacol 2015. epub ahead of publication
60. Parkinson Study G: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005, 62:241-8.
61. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-54. 10.1016/S0140-6736(05)71083-7.
62. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al.: Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2014, 29:229-37. 10.1002/mds.25751.
63. Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, et al.: Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol 2013, 20:271-80. 10.1111/j.1468-1331.2012.03840.x.
64. Jenner P: An overview of adenosine A2A receptor antagonists in Parkinson's disease. Int Rev Neurobiol 2014, 119:71-86.
65. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF: Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009, 15:406-13. 10.1016/j.parkreldis.2008.12.006.
66. Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, et al.: Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008, 23:2177-85. 10.1002/mds.22095.
67. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M: Japanese Istradefylline Study G. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010, 25:1437-43. 10.1002/mds.23107.
68. Mizuno Y, Kondo T: Japanese Istradefylline Study G. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord 2013, 28:1138-41. 10.1002/mds.25418.
69. Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, et al.: Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov Disord 2013, 28:817-20. 10.1002/mds.25395.
70. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, et al.: Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011, 10:221-9. 10.1016/S1474-4422(11)70012-6.
71. Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, et al.: Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e ][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther 2009, 330:294-303. 10.1124/jpet.108.149617.
72. Murata M, Hasegawa K, Kanazawa I: Japan Zonisamide on PDSG. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007, 68:45-50. 10.1212/01.wnl.0000250236.75053.16.
73. Miwa H: Zonisamide for the treatment of Parkinson's disease. Expert Rev Neurother 2007, 7:1077-83. 10.1586/14737175.7.9.1077.
74. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today 2010, 46:251-8. 10.1358/dot.2010.46.4.1490077.
75. Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al.: EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease. Mov Disord 2015. epub ahead of publication
76. Manson AJ, Turner K, Lees AJ: Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002, 17:1235-41. 10.1002/mds.10281.
77. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, et al.: Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005, 20:151-7. 10.1002/mds.20276.
78. Pilleri M, Antonini A: Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. Expet Opin Drug Saf 2015, 14:281-294. 10.1517/14740338.2015.988137.
79. Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Antonini A: Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Funct Neurol 2012, 27:147-54.
80. Nilsson D, Nyholm D, Aquilonius SM: Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 2001, 104:343-8. 10.1034/j.1600-0404.2001.00153.x.
81. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al.: Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014, 13:141-9. 10.1016/S1474-4422(13)70293-X.
82. Stocchi F, Vacca L, Ruggieri S, Olanow CW: Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005, 62:905-10.
83. Mancini F, Comi C, Oggioni GD, Pacchetti C, Calandrella D, Coletti Moja M, et al.: Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism Relat Disord 2014, 20:27-31. 10.1016/j.parkreldis.2013.09.007.
84. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P: Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011, 17:717-23. 10.1016/j.parkreldis.2011.02.018.
85. Todorova A, Jenner P, Ray CK: Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol 2014, 14:310-22. 10.1136/practneurol-2013-000741.
86. Brown RG, Landau S, Hindle JV, Playfer J, Samuel M, Wilson KC, et al.: Depression and anxiety related subtypes in Parkinson's disease. J Neurol Neurosurg Psychiatry 2011, 82:803-9. 10.1136/jnnp.2010.213652.
87. Chaudhuri KR, Schapira AH: Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-74. 10.1016/S1474-4422(09)70068-7.
88. Connolly B, Fox SH: Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics 2014, 11:78-91. 10.1007/s13311-013-0238-x.
89. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al.: Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014, 383:533-40. 10.1016/S0140-6736(13)62106-6.
90. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al.: Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:969-77. 10.1016/S1474-4422(10)70194-0.
91. Youdim MB, Kupershmidt L, Amit T, Weinreb O: Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism Relat Disord 2014,20(Suppl 1):S132-6.
92. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ: Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010, 133:3434-43. 10.1093/brain/awq268.
93. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, et al.: Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010, 75:1920-7. 10.1212/WNL.0b013e3181feb2ab.
94. Albanese A, Jenner P, Marsden CD, Stephenson JD: Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci Lett 1988, 87:46-50. 10.1016/0304-3940(88)90143-7.
95. Belaid H, Adrien J, Laffrat E, Tande D, Karachi C, Grabli D, et al.: Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion. J Neurosci 2014, 34:9124-33. 10.1523/JNEUROSCI.0181-14.2014.
96. Hyacinthe C, Barraud Q, Tison F, Bezard E, Ghorayeb I: D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism. Neurobiol Dis 2014, 63:20-4.
97. Schneider JS: Modeling Cognitive Deficits Associated with Parkinsonism in the Chronic-Low-Dose MPTP-Treated Monkey. In Animal Models of Cognitive Impairment. Edited by: Levin ED, Buccafusco JJ. Boca Raton (FL): CRC Press; 2006.
98. Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O: alpha-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis 2012, 47:258-67. 10.1016/j.nbd.2012.04.009.
99. McDowell K, Chesselet MF: Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis 2012, 46:597-606. 10.1016/j.nbd.2011.12.040.